Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Feb 12 2020 Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program
- Jan 6 2020 Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference
- Dec 23 2019 Anixa Biosciences to Present at Biotech Showcase 2020
- Dec 16 2019 Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test